Recombinant birch pollen allergoid (folding variant) - Allergopharma

Drug Profile

Recombinant birch pollen allergoid (folding variant) - Allergopharma

Alternative Names: rBet v1 - folding variant; rBet v1-FV

Latest Information Update: 15 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biomay
  • Developer Allergopharma
  • Class Allergens; Antiallergics; Tree pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Seasonal allergic rhinitis

Most Recent Events

  • 01 Sep 2011 Allergopharma completes a phase II trial in Seasonal allergic rhinitis in Germany (NCT01490411)
  • 24 Aug 2010 Phase II development is ongoing in Sweden
  • 24 Aug 2010 Phase III development is ongoing in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top